Volume 15, Issue 59 (7-2025)
NCMBJ 2025, 15(59): 63-71 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Soleimani S, Pouresmaeili F, Salahshourifar I. Investigating lncRNA GAPLINC Expression Level in Metastatic and Non-Metastatic Triple-Negative Breast Cancer Samples. NCMBJ 2025; 15 (59) :63-71
URL: http://ncmbjpiau.ir/article-1-1769-en.html
URL: http://ncmbjpiau.ir/article-1-1769-en.html
Department of Medical Genetics, Faculty of Medicine & Men’s Health and Reproductive Health Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran , pouresfar@gmail.com
Abstract: (17 Views)
Aim and Background: For the first time in this study, we investigated the expression level of lncRNA GAPLINC in metastatic and non-metastatic triple-negative breast cancer tissue samples using real-time PCR technique in order to find a possible marker in the diagnosis of metastatic triple-negative breast cancer.
Materials and Methods: After selecting the candidate lncRNA and designing primers on target gene sequence, the expression level of lncRNA GAPLINC was quantified using RT-qPCR with specific primers and SYBR Green on 50 fresh tissue samples, including 20 triple-negative metastatic and 20 non-metastatic breast cancer tissues, and 10 control tissue samples. The internal control used in this study included the β-actin gene, a more suitable control in terms of stability of expression compared to other genes in breast cancer molecular tests. GraphPad Prism software was used for statistical analysis and Adj. p-value < 0.05 was considered as a significant level.
Results: An increase was observed in the expression level of lncRNA GAPLINC in triple-negative breast cancer samples compared to non-metastatic triple-negative breast cancer samples, with Adj. p-value < 0.05.
Conclusion: GAPLINC can serve as a potential biomarker in the diagnosis of metastatic from non-metastatic breast cancer.
Materials and Methods: After selecting the candidate lncRNA and designing primers on target gene sequence, the expression level of lncRNA GAPLINC was quantified using RT-qPCR with specific primers and SYBR Green on 50 fresh tissue samples, including 20 triple-negative metastatic and 20 non-metastatic breast cancer tissues, and 10 control tissue samples. The internal control used in this study included the β-actin gene, a more suitable control in terms of stability of expression compared to other genes in breast cancer molecular tests. GraphPad Prism software was used for statistical analysis and Adj. p-value < 0.05 was considered as a significant level.
Results: An increase was observed in the expression level of lncRNA GAPLINC in triple-negative breast cancer samples compared to non-metastatic triple-negative breast cancer samples, with Adj. p-value < 0.05.
Conclusion: GAPLINC can serve as a potential biomarker in the diagnosis of metastatic from non-metastatic breast cancer.
Type of Study: Research Article |
Subject:
Genetics
Received: 2025/09/9 | Accepted: 2025/07/1 | Published: 2025/07/1
Received: 2025/09/9 | Accepted: 2025/07/1 | Published: 2025/07/1
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
